Naples Global Advisors LLC grew its stake in Novartis AG (NYSE:NVS) by 8.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,484 shares of the company’s stock after purchasing an additional 1,444 shares during the period. Naples Global Advisors LLC’s holdings in Novartis were worth $1,552,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. WFG Advisors LP grew its stake in shares of Novartis by 38.1% in the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock valued at $102,000 after purchasing an additional 337 shares during the period. Wealthcare Advisory Partners LLC bought a new stake in shares of Novartis in the 3rd quarter valued at approximately $106,000. Cable Hill Partners LLC grew its stake in shares of Novartis by 588.8% in the 3rd quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock valued at $112,000 after purchasing an additional 1,107 shares during the period. Harding Loevner LP bought a new stake in shares of Novartis in the 2nd quarter valued at approximately $146,000. Finally, Sawyer & Company Inc bought a new stake in shares of Novartis in the 4th quarter valued at approximately $183,000. Institutional investors own 10.85% of the company’s stock.
Several research firms have recently weighed in on NVS. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a research note on Thursday. Nord/LB reiterated a “neutral” rating on shares of Novartis in a research note on Tuesday, January 2nd. Bank of America lowered Novartis from a “neutral” rating to an “underperform” rating in a research note on Wednesday, December 6th. Leerink Swann upped their price objective on Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Finally, Zacks Investment Research lowered Novartis from a “buy” rating to a “hold” rating in a research note on Friday, October 6th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. Novartis has an average rating of “Hold” and a consensus price target of $85.32.
Novartis AG (NVS) traded down $0.47 during midday trading on Friday, reaching $86.41. The company had a trading volume of 1,523,700 shares, compared to its average volume of 1,071,025. The company has a market cap of $226,090.00, a price-to-earnings ratio of 30.75, a PEG ratio of 2.32 and a beta of 0.74. Novartis AG has a 1-year low of $69.53 and a 1-year high of $87.29. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08.
Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, topping the Zacks’ consensus estimate of $1.25 by $0.04. The business had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. Novartis had a return on equity of 15.77% and a net margin of 13.73%. Novartis’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.23 EPS. research analysts anticipate that Novartis AG will post 4.79 earnings per share for the current year.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.